Modifying disability in progressive multiple sclerosis

The Lancet

Volumn 383, Issue 9936, 2014, Pages 2189-2191

  Palace, Jacqueline ^a,b   Robertson, Neil ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN; IMMUNOMODULATING AGENT;

ANTIINFLAMMATORY ACTIVITY; BRAIN ATROPHY; BRAIN SIZE; DISEASE DURATION; EARLY INTERVENTION; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS IMPACT SCALE 29; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROIMAGING; NEUROPROTECTION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PHYSICAL DISABILITY; PRIORITY JOURNAL; RELAPSE; ASSESSMENT OF HUMANS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; MULTIPLE SCLEROSIS IMPACT SCALE;

BRAIN; DISABLED PERSONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SIMVASTATIN;

EID: 84903301234     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62641-0     Document Type: Note

References (15)

1. Mackenzie IS, Morant SV, Bloomfield GA, Macdonald TM, O'Riordan JI. Changing face of multiple sclerosis in the United Kingdom 1990-2010. An incidence and prevalence study. J Neurol Neurosurg Psychiatry 2013; 84: e2.
2. Orton SM, Herrera BM, Yee IM, et al, for the Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-36.
3. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-38.
4. Tremlett H, Zhao Y, Joseph J, Devonshire V, for the UBCMS Clinical Neurologists. Relapses in mu ltiple sclerosis are age-and time-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 1368-74.
5. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological b asis of clinical progression in multiple sclerosis. Acta Neuropathol 2011; 122: 155-70.
6. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206: 135-37.
7. Hirst C, Ingram G, Swingler R, Compston DA, Pickersgill T, Robertson NP. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry 2008; 79: 1137-43.
8. Zajicek J, Ball S, Wright D, et al, for the CUPID Investigator Group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12: 857-65.
9. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-66.
10. Popescu V, Agosta F, Hulst HE, et al, for the MAHNIMS Study Group. Brain atrophy and lesion load pre dict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082-91.
11. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2013; 75: 43-49.
12. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secon dary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014; published online March 19. http://dx.doi.org/10.1016/S0140-6736(13)62242- 4.
13. Sormani MP, Cutter G, Comi G, et al. Evaluating the relationship between laquinimod's effects on relapses and disability progression. 29th European Committee for Treatment and Research in Multiple Sclerosis; Cophenhagen, Denmark; Oct 2-5, 2013; p1080.
14. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47.
15. Pickin M, Cooper CL, Chater T, et al. The multiple sclerosis risk sharing scheme monitoring study-early results and lessons for the future. BMC Neurol 2009; 9: 1.